Editorial

Diabetes mellitus and its associated cardiometabolic disorders continue to expand rapidly across low-and middle-income countries (LMICs), particularly in South Asia and the Middle East.According to the International Diabetes Federation Diabetes Atlas (11th edition), the global burden of diabetes continues to rise at an alarming pace, with a disproportionate impact on LMICs where health-system preparedness often lags behind disease expansion. 1While remarkable therapeutic advances have transformed diabetes care globally, the translation of these innovations into routine clinical practice remains uneven.The articles featured in this issue of the Journal of Diabetes and Endocrine Clinics collectively highlight a central reality: improving outcomes in diabetes today depends not only on new therapies but also on strengthening detection strategies, optimizing care pathways, and addressing contextual barriers to treatment delivery.One of the most striking developments in contemporary diabetes therapeutics is the emergence of dual incretin-based therapies such as tirzepatide.As highlighted by Ghazi et al, tirzepatide represents a major step forward in addressing the intertwined epidemics of type 2 diabetes mellitus (T2DM) and obesity, offering substantial glycemic improvement along with clinically meaningful weight reduction. 2However, successful integration of such therapies into routine clinical practice across LMIC settings will depend on affordability, accessibility, and system-level preparedness.Equally important to therapeutic advances is the question of how best to identify metabolic risk early and accurately.The populationbased study from rural Bangladesh demonstrated that fasting plasma glucose may outperform glycated hemoglobin for identifying metabolic syndrome in nondiabetic adults in South Asian populations. 3These findings reinforce the importance of adapting diagnostic strategies to regional biological and epidemiological contexts rather than relying exclusively on extrapolated international thresholds.Preventive strategies across the life course also emerge as a recurring theme in this issue.The systematic review examining lifestyle interventions among women with gestational diabetes mellitus in the Indian subcontinent highlights both the promise and the limitations of current approaches. 4While lifestyle modification programs show encouraging benefits in reducing progression to type 2 diabetes, variability in intervention design, duration, and cultural adaptation continues to limit scalability.Strengthening postpartum prevention strategies remains a critical priority for the region.At the health-system level, therapeutic inertia continues to represent a major barrier to achieving optimal metabolic outcomes.The retrospective analysis of referral pathways from primary care to specialist care in India highlights the underutilization of contemporary cardiometabolic therapies despite a high burden of obesity and hypertension among individuals with diabetes. 5These findings underscore the need for structured referral pathways, decision-support tools, and improved guideline implementation across the primary-specialist interface.Importantly, diabetes care challenges extend beyond pharmacotherapy and screening strategies.The letter addressing temperaturecompromised insulin storage in resource-limited environments draws attention to an often-overlooked determinant of glycemic instability, particularly among children with type 1 diabetes. 6Ensuring insulin potency through reliable storage solutions represents a fundamental yet under recognized component of diabetes equity worldwide.Taken together, the contributions in this issue illustrate the complexity of modern diabetes care across diverse healthcare settings.They remind us that effective diabetes management requires coordinated action across multiple levels-early detection, culturally appropriate prevention strategies, rational pharmacotherapy, and strengthened health-system infrastructure.As therapeutic possibilities expand, the next frontier lies in ensuring that these advances translate into meaningful improvements in outcomes for populations most affected by the diabetes epidemic.